Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

11.70
+0.60005.41%
Post-market: 11.700.00000.00%16:10 EDT
Volume:1.04M
Turnover:12.10M
Market Cap:1.17B
PE:-7.96
High:11.99
Open:11.30
Low:11.29
Close:11.10
52wk High:14.93
52wk Low:3.90
Shares:100.36M
Float Shares:86.55M
Volume Ratio:0.60
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4700
EPS(LYR):-1.4747
ROE:-41.27%
ROA:-26.17%
PB:3.05
PE(LYR):-7.93

Loading ...

Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research

TIPRANKS
·
Nov 18, 2025

Oric Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 17, 2025

Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications

TIPRANKS
·
Nov 16, 2025

Top Calls on Wall Street: Nvidia, Applied Materials, Nu Holdings, Lowe's, Shake Shack, Gap & More

Tiger Newspress
·
Nov 15, 2025

Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target

TIPRANKS
·
Nov 15, 2025

Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright

TIPRANKS
·
Nov 15, 2025

Oric Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $23 From $19

THOMSON REUTERS
·
Nov 14, 2025

Oric Pharmaceuticals : Oppenheimer Raises Target Price to $15 From $12

THOMSON REUTERS
·
Nov 14, 2025

Oric Pharmaceuticals (ORIC) Gets a Buy from Ladenburg Thalmann & Co.

TIPRANKS
·
Nov 14, 2025

Promising Developments and Strong Cash Position Justify Buy Rating for ORIC Pharmaceuticals

TIPRANKS
·
Nov 14, 2025

Oric Pharmaceuticals, Inc. : Wells Fargo Cuts Target Price to $19 From $20

THOMSON REUTERS
·
Nov 14, 2025

Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results

TIPRANKS
·
Nov 14, 2025

Oric Pharmaceuticals reports Q3 EPS (33c), consensus (40c)

TIPRANKS
·
Nov 14, 2025

ORIC Pharmaceuticals Q3 EPS $(0.33) Beats $(0.42) Estimate

Benzinga
·
Nov 14, 2025

ORIC Pharmaceuticals Q3 Net Income USD -32.587 Million

Reuters
·
Nov 14, 2025

Oric Pharmaceuticals reports third quarter 2025 financial results and updates on clinical programs

Reuters
·
Nov 14, 2025

Oric Pharmaceuticals Inc - Qtrly Net Loss per Share, Basic and Diluted $0.33

THOMSON REUTERS
·
Nov 14, 2025

Oric Pharmaceuticals Reports Promising Phase 1b Results for ORIC-944 in Prostate Cancer Trial

Reuters
·
Nov 14, 2025

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

GlobeNewswire
·
Nov 14, 2025

Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employee

Reuters
·
Nov 08, 2025